Related Experiment Video
Updated: Jun 14, 2025
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1
M Sereno1, A Collazo-Lorduy2, Y Garitaonaindia2
1Department of Medical Oncology. Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain; FIIB HUIS HHEN, Madrid, Spain; IMDEA Precision Nutrition and Cancer Program, Clinical Oncology Group, IMDEA Food Institute, CEI UAM, CSIC, Madrid, Spain.
Background:
The adoption of combined chemotherapy (CT) and immunotherapy (IO) has advanced neoadjuvant therapy (NA) for non-small cell lung cancer (NSCLC), but data on functional impacts are limited. This multicenter retrospective study evaluates respiratory function in NSCLC patients undergoing NA.
Methods:
From 2020 to 2024, 186 patients treated with CT or CT-IO (anti-PD-1/PD-L1) were analyzed. Respiratory tests (DLCO, FEV1, FVC) pre- and post-NA were compared, alongside clinical, pathological, and surgical variables.
Results:
Median age: 68; 66.6 % male; 93 % smokers/ex-smokers, histologies: Squamous and adenocarcinoma (46 % each), DLCO decline was greater in CT-IO vs. CT (-12.6 % vs. -7.8 %, p = 0.007) and CT-IO showed increased FEV1 (+3.8 % vs. -2.5 %, p = 0.001) and FVC (+3.7 % vs. -0.7 %, p = 0.003), surgery rate: 85.7 % (lobectomy most common at 83.3 %) and no differences in complications were found except for 9 immune-mediated events in CT-IO.
Conclusions:
CT-IO impacts DLCO more but improves FEV1 and FVC compared to CT. These findings warrant further validation in prospective studies.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy